Top Page
Lucid Diagnostics
(NASDAQ:LUCD)
Lucid Diagnostics (LUCD) vs. SPDR S&P 500 ETF (SPY)
Lucid Diagnostics Business Overview & Revenue Model
Lucid Diagnostics Earnings Call Summary
Lucid Diagnostics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.21B | 4.35M | 2.43M | 377.00K | 500.00K | 0.00 |
| Gross Profit | -488.29M | -3.92M | -6.05M | -3.24M | -85.00K | 0.00 |
| EBITDA | -10.00B | -44.34M | -49.75M | -54.23M | -27.41M | 482.00 |
| Net Income | -10.44B | -45.53M | -52.67M | -56.17M | -28.08M | -8.28M |
Balance Sheet | ||||||
| Total Assets | 53.20M | 30.71M | 27.27M | 32.51M | 59.00M | 2.19M |
| Cash, Cash Equivalents and Short-Term Investments | 47.33M | 22.36M | 18.90M | 22.47M | 53.66M | 111.00K |
| Total Debt | 24.34M | 21.25M | 15.26M | 2.00M | 0.00 | 0.00 |
| Total Liabilities | 27.36M | 25.32M | 29.58M | 9.46M | 4.26M | 15.71M |
| Stockholders Equity | 25.84M | 5.39M | -2.31M | 23.05M | 54.74M | -13.52M |
Cash Flow | ||||||
| Free Cash Flow | -44.18M | -44.79M | -33.04M | -30.59M | -18.53M | -5.63M |
| Operating Cash Flow | -43.78M | -44.14M | -32.82M | -29.68M | -17.67M | -5.63M |
| Investing Cash Flow | -405.00K | -646.00K | -221.00K | -4.11M | -862.00K | 0.00 |
| Financing Cash Flow | 77.03M | 48.25M | 29.46M | 2.61M | 72.08M | 5.58M |
Lucid Diagnostics Technical Analysis
Lucid Diagnostics Risk Analysis
Lucid Diagnostics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $103.88M | -20.78 | 3.64% | ― | 16.88% | ― | |
60 Neutral | ― | ― | ― | ― | -4.15% | 3.49% | |
55 Neutral | $289.04M | ― | ― | ― | 26.83% | -52.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $70.08M | -1.20 | -73.73% | ― | 15.59% | 4.13% | |
44 Neutral | $147.32M | ― | -331.24% | ― | 5.01% | 20.76% | |
42 Neutral | $114.35M | ― | -1746.27% | ― | 20.59% | 18.61% |
Lucid Diagnostics Corporate Events
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company specializing in cancer prevention, particularly focusing on gastroesophageal reflux disease (GERD) and its potential to develop into esophageal cancer. The company utilizes innovative technologies like EsoGuard and EsoCheck for early detection of esophageal conditions.
Lucid Diagnostics Inc. recently held its earnings call, revealing a mixed sentiment. While the company celebrated strategic achievements, such as strengthening its market access team and making positive strides towards Medicare coverage, it also faced challenges. Flat revenue growth and ongoing reimbursement issues were highlighted as obstacles impacting short-term financial performance.
Lucid Diagnostics reported its third-quarter 2025 financial results, highlighting the processing of 2,841 EsoGuard tests and revenue of $1.2 million. The company ended the quarter with over $47 million in cash, extending its financial runway through 2026. A significant development was the unanimous expert consensus at the Multi-Jurisdictional Contractor Advisory Committee meeting supporting Medicare coverage for EsoGuard, marking a crucial step towards securing transformative Medicare coverage. The company also strengthened its market access team and announced upcoming initiatives, including a summit focused on cancer prevention in the fire service.
The most recent analyst rating on (LUCD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
On September 25, 2025, Lucid Diagnostics announced the appointment of John R. Palumbo to its Board of Directors, effective September 22, 2025. Palumbo brings 40 years of healthcare leadership experience, including guiding early-stage companies through commercial growth. His appointment is expected to support Lucid’s strategic initiatives as it approaches key commercial milestones, particularly in addressing unmet needs in cancer prevention with its EsoGuard product.
The most recent analyst rating on (LUCD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
On September 11, 2025, Lucid Diagnostics Inc. announced the closing of its underwritten public offering of 28,750,000 shares of common stock at $1.00 per share, generating approximately $26.9 million in net proceeds. The funds are intended for working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners, and Maxim Group LLC as co-manager. This offering, made under an existing shelf registration, aims to strengthen Lucid’s financial position and support its ongoing operations in the cancer prevention diagnostics market.
The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
On September 10, 2025, Lucid Diagnostics entered into an underwriting agreement for a public offering of its common stock, pricing each share at $1.00. The offering, managed by Canaccord Genuity LLC and BTIG, LLC, aims to raise $25 million, with potential to increase to $28.75 million if additional shares are purchased. The proceeds will support working capital and general corporate purposes, with the sale expected to close on September 11, 2025, subject to customary conditions.
The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
Lucid Diagnostics Inc. recently held its earnings call, revealing a cautiously optimistic outlook for the company’s future. The call was marked by positive developments such as significant revenue growth and successful partnerships, alongside challenges like revenue recognition and high operational costs. The focus remains on achieving Medicare coverage, a key milestone for the company.
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, specifically targeting patients with gastroesophageal reflux disease (GERD) at risk of developing esophageal cancer. The company offers EsoGuard, a DNA assay, and EsoCheck, a non-invasive cell collection device, both based on patented technology licensed from Case Western Reserve University.
Lucid Diagnostics reported financial results for the second quarter of 2025, with revenue of $1.2 million from 2,756 processed EsoGuard tests. The company ended the quarter with over $30 million in cash, extending its financial runway into 2026. Lucid is advancing towards securing Medicare coverage for EsoGuard, with a significant advisory committee meeting scheduled for September 4, 2025. The company has also initiated testing under a new insurance policy and partnered with Hoag to expand access to its testing programs. Additionally, Lucid joined the Russell 2000 and 3000 Indexes, enhancing its visibility among institutional investors.
The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.